S&P 500 7,743.41 +0.51%
Nasdaq 27,068.72 +0.48%
S&P/TSX 35,800.89 +0.26%
Apple 341.07 +1.53%
Nvidia 225.07 +0.22%
Microsoft 516.17 +3.66%
Shopify 201.20 −2.00%
Royal Bank 285.63 +1.25%
CAD/USD 0.7072 +0.04%
CLOSED · 01:45 ET
Market ClerkRecap
Sat Sep 26 · markets closed4 signals on Sep 25151 insider buys this week · $292.9MCIRO short report next: Sep 29The week ahead

REPL

Replimune Group, Inc.
NASDAQ · HEALTH CARE · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
12.36
−0.24 −1.90%
USD · close Sep 25

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

Financials

SEC XBRL · 47 PERIODS · WHOLE USD

By quarter

PeriodRevenueYoYGross marginOperating incomeNet incomeYoYEPSOp. cash flowCapexFree cash flowFiled
Q1 2027 · Jun 30———−$68.2M−$69.8M—-0.72−$75.7M$6K−$75.7MAug 14
Q4 2026 · Mar 31derived———−$73.3M−$73.2M—-0.76−$56.2M$5K−$56.2MJun 29
Q3 2026 · Dec 31———−$71.9M−$70.9M—-0.77−$66M$135K−$66.1MFeb 3
Q2 2026 · Sep 30———−$84.3M−$83.1M—-0.90−$81.2M$1.3M−$82.6MFeb 3
Q1 2026 · Jun 30———−$90.4M−$86.7M—-0.95−$77M$2.7M−$79.8MAug 14
Q4 2025 · Mar 31derived———−$79.3M−$74.1M—-0.82−$53.7M$1.1M−$54.9MJun 29
Q3 2025 · Dec 31———−$66M−$66.3M—-0.79−$50.7M$1.8M−$52.5MFeb 3
Q2 2025 · Sep 30———−$58.9M−$53.1M—-0.68−$38.6M$2.1M−$40.7MFeb 3
Q1 2025 · Jun 30———−$57.4M−$53.8M—-0.78−$49.2M$1.7M−$50.8MFeb 3
Q4 2024 · Mar 31derived———−$58.8M−$55.1M—-0.82−$46.2M$1.7M−$47.9MMay 22
Q3 2024 · Dec 31———−$56.5M−$51.1M—-0.77−$47.1M$1.7M−$48.8MFeb 12
Q2 2024 · Sep 30———−$63.8M−$60M—-0.90−$43.6M$1.8M−$45.3MFeb 12

By fiscal year

YearRevenueGross marginOperating incomeNet incomeNet marginEPSOp. cash flowCapexFree cash flowBuybacksDividends paid
FY2026 · to Mar 31——−$319.9M−$313.9M—-3.38−$280.3M$4.2M−$284.6M——
FY2025 · to Mar 31——−$261.6M−$247.3M—-3.07−$192.3M$6.7M−$198.9M——
FY2024 · to Mar 31——−$234.8M−$215.8M—-3.24−$185.5M$5.7M−$191.1M——
FY2023 · to Mar 31——−$177.1M−$174.3M—-2.99−$128.1M$2.3M−$130.3M——
FY2022 · to Mar 31——−$118.3M−$118M—-2.26−$82.2M$2.3M−$84.5M——
FY2021 · to Mar 31——−$80M−$80.9M—-1.75−$61.4M$2.4M−$63.8M——

Every number comes from Replimune Group, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.

Watch REPL. Know when insiders buy.
One email the day a filing lands. Free.